Sensory Organ Drugs - Jordan

Jordan

The Sensory Organ Drugs market in Jordan is forecasted to achieve a revenue of US$7.25m by 2024.
This projection anticipates a steady annual growth rate (CAGR 2024-2029) of -3.59%, leading to a market volume of US$6.04m by 2029.
In terms of global comparison, United States is expected to generate the highest revenue in this market, amounting to US$13,980.00m in 2024.
Jordan's pharmaceutical market is witnessing a growing demand for sensory organ drugs, driven by increasing healthcare awareness and a rising aging population.

Key regions: Australia, France, Brazil, Italy, India

Market

Region

Region comparison

Currency

Analyst Opinion

The Sensory Organ Drugs market in Jordan has been experiencing steady growth in recent years.

Customer preferences: Customers in Jordan are increasingly seeking out medications that address sensory organ ailments, such as hearing loss, vision impairment, and vertigo. This trend is in line with the global rise in sensory organ diseases, particularly among aging populations.

Trends in the market: The Sensory Organ Drugs market in Jordan is being driven by a combination of factors, including an aging population, an increase in chronic diseases, and a rise in disposable income. As the population ages, the incidence of sensory organ diseases is expected to rise. Additionally, as people live longer, they are more likely to develop chronic diseases that affect the sensory organs. Finally, as disposable income rises, more people are able to afford medications that treat these conditions.

Local special circumstances: One factor that is unique to the Jordanian market is the prevalence of consanguineous marriages, which can increase the likelihood of genetic disorders that affect the sensory organs. This may lead to a greater need for medications that address these conditions.

Underlying macroeconomic factors: The Jordanian economy has been growing steadily in recent years, which has led to an increase in disposable income. Additionally, the government has made efforts to improve healthcare access and quality, which has led to an increase in demand for medications. However, the market is also subject to regulatory changes and pricing pressures, which can impact growth.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.